How do doctors catch prostate cancer before it announces itself with symptoms? The answer is PSA testing—a blood test that measures prostate-specific antigen levels. It’s the go-to screening tool, though doctors sometimes pair it with a digital rectal exam for good measure.
But here’s the thing: there’s no universal agreement on who should get screened and when. Guidelines are all over the map. Most organizations push for “shared decision-making,” which is medical speak for “you and your doctor need to hash this out together.”
The typical recommendation? Start screening at 50 for average-risk men, every two to four years until age 69. Black men and those with family history might start earlier—around 40 to 45. After 70? Most experts say forget about it. The risks outweigh the benefits.
Start at 50, earlier if you’re high-risk, and call it quits at 70—that’s the screening playbook most doctors follow.
The numbers tell a sobering story. Screen 1,000 men, and you might prevent about one prostate cancer death. That’s it. You’ll also catch roughly three cases before they spread. Sounds modest, doesn’t it?
The flip side is uglier. Overdiagnosis happens in 20 to 50 percent of screen-detected cancers. Translation: men get diagnosed and treated for cancers that would never have killed them. False positives create anxiety and lead to unnecessary biopsies, which come with their own risks—infection, bleeding, urinary problems.
Then there’s treatment fallout. Incontinence and erectile dysfunction aren’t rare complications. They’re real possibilities that can devastate quality of life, especially for men whose cancers weren’t particularly dangerous to begin with.
The medical establishment can’t even agree on screening intervals. The USPSTF says men 55 to 69 should make informed decisions with their doctors, but advises against routine screening after 70. The American Cancer Society wants annual screening for men with PSA levels above 2.5 ng/mL. Many doctors now recommend using age-adjusted thresholds rather than the traditional 4 ng/mL cutoff for determining elevated PSA levels.
Active surveillance has emerged as a middle ground—monitoring low-risk cancers instead of immediately treating them. It reduces overtreatment but requires psychological fortitude. The approach has gained significant traction, with usage rates jumping from just 10 percent in the mid-2000s to over 40 percent by the early 2010s.
The bottom line? PSA screening exists in a gray zone where benefits and harms duke it out, and individual circumstances matter more than blanket recommendations.
